2015
DOI: 10.1038/ng.3338
|View full text |Cite
|
Sign up to set email alerts
|

Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney

Abstract: Clear cell sarcoma of the kidney (CCSK) is one of the major pediatric renal neoplasms, but its associated genetic abnormalities are largely unknown. We identified internal tandem duplications in the BCOR gene (BCL6 corepressor) affecting the C terminus in 100% (20/20) of CCSK tumors but in none (0/193) of the other pediatric renal tumors. CCSK tumors expressed only an aberrant BCOR allele, indicating a close correlation between BCOR aberration and CCSK tumorigenesis.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

16
146
1

Year Published

2016
2016
2022
2022

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 135 publications
(163 citation statements)
references
References 21 publications
(6 reference statements)
16
146
1
Order By: Relevance
“…3A). 7,9,18,19 Two of the BCOR ITD-positive CCSKs were diagnosed in adult patients, both 29 year-old male patients, and the third being a 5-year-old boy.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…3A). 7,9,18,19 Two of the BCOR ITD-positive CCSKs were diagnosed in adult patients, both 29 year-old male patients, and the third being a 5-year-old boy.…”
Section: Resultsmentioning
confidence: 99%
“…All reads were independently aligned with STAR (ver 2.3) 12 and TopHat2 (ver 2.0.14) 13 against the human reference genome (hg19). Based on the known genetic abnormalities reported in CCSK, 7,8 the reads were also investigated manually for YWHAE - NUTM2B/E fusion and BCOR ITD. The mRNA expression of BCOR and PEA3 family genes, including ETV1, ETV4 and ETV5 , were analyzed and compared to other sarcomas.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Furthermore, development of targeted therapies, based on specific molecular aberrations of CCSK, is desirable for this group of patients. Potential targets for new treatments for CCSK patients might be BCOR ITDs (identified in about 80-90% of CCSKs), hypermethylation of TCF21 (identified in about 80-90% of CCSKs) or the YWHAE-NUTM2 fusion gene (identified in 5-10% of CCSKs) 9,13,14 . Finally, immunotherapy might be a therapeutic option for patients with CCSK in the future 73 .…”
Section: Future Perspectivesmentioning
confidence: 99%
“…Long a mystery, genetic alterations underlying CCSK have been delineated in the past decade. The majority (>90%) of CCSK harbor internal tandem duplications (ITD) in the last exon of the BCOR ( Bcl6 interacting co-repressor) gene, which in CCSK is thought to regulate gene transcription through an epigenetic silencing mechanism 6,7,8 . A smaller subset of CCSK harbor a YWHAE-NUTM2B gene fusion resulting from a t(10;17)(q22.3;p13.3) translocation which is identical to that seen in high grade endometrial stromal sarcoma 9,10 .…”
Section: Introductionmentioning
confidence: 99%